RADAR-CNS MS study recruits first participants

The RADAR-CNS (Remote Assessment of Disease and Relapse – Central Nervous System) project has recruited its first participants to the multiple sclerosis (MS) component of the program in Milan, Italy.

The participants visited Ospedale San Raffaele (HSR) in Milan, Italy, to enrol in MS study 2. They received initial guidance and testing using the Fitbit charge 2 device and completed the initial tests and evaluation for the study.

The Fitbit device will be worn for up to 24 hours per day. It will capture information about mobility, heart rate and sleep quality. In the following weeks the participants will also receive a chest worn device, the eFaros, which will be used for a week every 3 months to better characterize balance, gait variability, falls and heart rate variability.

In RADAR-CNS there are two clinical studies involving MS patients. Both studies are multicenter, observational non-randomized, non-interventional studies conducted in Milan, Italy Barcelona, Spain and Copenhagen, Denmark.

Study 1 focuses on mood changes (in particular on depressive feelings) in people with a recent diagnosis of MS. In this study, 240 MS participants will be included. 

Study 2 focuses on changes in disability and fatigue over time. In this study, 400 participants that are affected by relapsing remitting or secondary progressive MS will be recruited.

Giancarlo Comi, Professor of Neurology, Chairman of the Department of Neurology, and Director of the Institute of Experimental Neurology at Vita-Salute San Raffaele University, Milan, Italy said, ‘We are very pleased to have recruited our first participant in Milan. It’s an exciting time for us as we enrol and recruit more people to our MS studies.’

The clinical studies on MDD (major depressive disorder) recruited the first participants in December 2017, and the clinical study on epilepsy got underway in June 2017.